Compare Merck & Co., Inc. (MRK) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares Silver Trust — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while iShares Silver Trust trades at $54.18. The key difference: Merck & Co., Inc. pays a 2.73% dividend while iShares Silver Trust pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| MRK | SLV | |
|---|---|---|
Market Cap | $307.25B | — |
Sector | Health | — |
52-Week High | $129.52 | $105.57 |
52-Week Low | $77.60 | $33.32 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
SLV, the iShares Silver Trust ETF, trades at $53.08, up 4.53% on the day, amid a broader precious metals rebound. Technical indicators are predominantly bearish, with moving averages signaling sell pressure, though short-term RSI suggests potential oversold conditions. Recent news highlights silver's sensitivity to interest rate expectations and geopolitical tensions, with supply deficits and industrial demand providing fundamental support. The ETF lacks traditional valuation metrics like P/E or P/B as it tracks physical silver.
The outlook for SLV hinges on macroeconomic factors, including Fed policy and silver's dual role as a monetary and industrial metal. Risks include persistent rate hikes and dollar strength, but long-term demand drivers offer appreciation potential. Investors should weigh silver's volatility against its hedge attributes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
